Article
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting.
Nature communications - 16 Jul 2021
Bear Adham S, Blanchard Tatiana, Cesare Joseph, Ford Michael J, Richman Lee P, Xu Chong, Baroja Miren L, McCuaig Sarah, Costeas Christina, Gabunia Khatuna, Scholler John, Posey Avery D, O'Hara Mark H, Smole Anze, Powell Daniel J, Garcia Benjamin A, Vonderheide Robert H, Linette Gerald P, Carreno Beatriz M
Abstract excerpt
Activating RAS missense mutations are among the most prevalent genomic alterations observed in human cancers and drive oncogenesis in the three most lethal tumor types. Emerging evidence suggests mutant KRAS (mKRAS) may be targeted immunologically, but mKRAS epitopes remain poorly defined. Here we employ a multi-omics approach to characterize HLA class I-restricted mKRAS epitopes. We provide proteomic evidence of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.